BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 26707054)

  • 21. The UKCTOCS experience--reasons for hope?
    Menon U; Kalsi J; Jacobs I
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S18-20. PubMed ID: 22543913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
    Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
    JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
    Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
    Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
    Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
    Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
    Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
    J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gentry-Maharaj A; Glazer C; Burnell M; Ryan A; Berry H; Kalsi J; Woolas R; Skates SJ; Campbell S; Parmar M; Jacobs I; Menon U
    BMJ Open; 2017 Mar; 7(3):e011822. PubMed ID: 28264823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening Cuts Ovarian Cancer Mortality.
    Cancer Discov; 2016 Feb; 6(2):OF1. PubMed ID: 26758578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS.
    Taylor JA; Burnell M; Ryan A; Karpinskyj C; Kalsi JK; Taylor H; Apostolidou S; Sharma A; Manchanda R; Woolas R; Campbell S; Parmar M; Singh N; Jacobs IJ; Menon U; Gentry-Maharaj A
    BJOG; 2022 Jan; 129(1):110-118. PubMed ID: 34555263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
    Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
    [No Abstract]   [Full Text] [Related]  

  • 32. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Pinsky PF; Yu K; Kramer BS; Black A; Buys SS; Partridge E; Gohagan J; Berg CD; Prorok PC
    Gynecol Oncol; 2016 Nov; 143(2):270-275. PubMed ID: 27615399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis.
    Burnell M; Gentry-Maharaj A; Skates SJ; Ryan A; Karpinskyj C; Kalsi J; Apostolidou S; Singh N; Dawnay A; Woolas R; Fallowfield L; Campbell S; McGuire A; Jacobs IJ; Parmar M; Menon U
    Trials; 2021 Mar; 22(1):173. PubMed ID: 33648562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial.
    Atkin W; Wooldrage K; Parkin DM; Kralj-Hans I; MacRae E; Shah U; Duffy S; Cross AJ
    Lancet; 2017 Apr; 389(10076):1299-1311. PubMed ID: 28236467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar.
    Kalsi JK; Ryan A; Gentry-Maharaj A; Margolin-Crump D; Singh N; Burnell M; Benjamin E; Apostolidou S; Habib M; Massingham S; Karpinskyj C; Woolas R; Widschwendter M; Fallowfield L; Campbell S; Skates S; McGuire A; Parmar M; Jacobs I; Menon U
    Trials; 2021 Jan; 22(1):88. PubMed ID: 33494753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
    J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.
    Jacobs I; Gentry-Maharaj A; Burnell M; Manchanda R; Singh N; Sharma A; Ryan A; Seif MW; Amso NN; Turner G; Brunell C; Fletcher G; Rangar R; Ford K; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Scott I; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Skates SJ; Fallowfield L; Parmar M; Campbell S; Menon U
    Lancet Oncol; 2011 Jan; 12(1):38-48. PubMed ID: 21147030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer screening: Current status and future directions.
    Nash Z; Menon U
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
    Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
    Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.